Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia

NCT06722235 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06722235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06722235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
February 27, 2025
Completion date
March 16, 2028
Enrollment
171 (estimated)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura (itp)